| **Title**     | Historical perspective of living donor liver transplantation |
|--------------|-------------------------------------------------------------|
| **Author(s)**| Chan, SC; Fan, ST                                            |
| **Citation** | World Journal Of Gastroenterology, 2008, v. 14 n. 1, p. 15-21 |
| **Issued Date** | 2008                                                      |
| **URL**      | http://hdl.handle.net/10722/83318                           |
| **Rights**   | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
Historical perspective of living donor liver transplantation

See Ching Chan, Sheung Tat Fan

See Ching Chan, Sheung Tat Fan, Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
Correspondence to: Professor Sheung Tat Fan, Department of Surgery, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China. stfan@hku.hk
Telephone: +852-28554703  Fax: +852-28184407
Received: August 21, 2007  Revised: September 28, 2007

Abstract

Living donor liver transplantation (LDLT) has gone through its formative years and established as a legitimate treatment when a deceased donor liver graft is not timely or simply not available at all. Nevertheless, LDLT is characterized by its technical complexity and ethical controversy. These are the consequences of a single organ having to serve two subjects, the donor and the recipient, instantaneously. The transplant community has a common ground on assuring donor safety while achieving predictable recipient success. With this background, a reflection of the development of LDLT may be appropriate to direct future research and patient-care efforts on this life-saving treatment alternative.

© 2008 WJG. All rights reserved.

Key words: Historical perspective; Living donor liver transplantation

http://dx.doi.org/10.3748/wjg.14.15
Chan SC, Fan ST. Historical perspective of living donor liver transplantation. World J Gastroenterol 2008; 14(1): 15-21

http://www.wjgnet.com/1007-9327/14/15.asp

INTRODUCTION

Living donor liver transplantation (LDLT) has been rapidly growing and evolving since its debut in 1989[1], while deceased donor liver transplantation (DDLT) had already been a standard procedure for a decade[2,3]. LDLT being the legitimate remedy for the refractory shortage of deceased donor liver grafts is characterized by its technical complexity and ethical controversies.

In 1963, Starzl described in detail three cases of DDLT. The first recipient was a 3-year-old boy with biliary atresia and died from intra-operative hemorrhage. The other two recipients were adult males with primary liver cancer. Both succumbed to pulmonary embolism 7 and 22 d after transplantation. These three cases, though ended up in hospital mortality, established the technical feasibility of liver transplantation in human[4]. Only four years later, long survivals were achieved in four DDLT recipients[5]. To become a reliable treatment modality for end-stage liver diseases of a number of etiologies, DDLT has taken two important steps: the clinical use of calcineurin inhibitor - cyclosporine A[6] and improvement of graft preservation techniques by hypothermic perfusion utilizing University of Wisconsin solution[7].

Soon after DDLT had become a standard clinical practice, it outstripped the supply of deceased donor liver grafts. The shortage of pediatric deceased donor liver grafts was even more marked. To overcome size disparity of the graft and the child recipient, reduced-size liver transplantation was devised by Bismuth in 1984[8]. Through extension of this concept, split-graft liver transplantation was then developed by Pichlmayr in 1988[9]. This enables transplanting one more recipient and circumventing graft size discrepancy in one go. The first series was reported by Broelsch in 1990[10].

BIRTH OF LIVING DONOR LIVER TRANSPLANTATION

Experience gained from in-situ donor hepatectomy in reduced-size and split-graft DDLT paved the way for LDLT, an idea proposed by Smith as early as 1969[11]. When harvesting was performed on the living donor, much more technical ingenuity was required. The first attempt was made by Ratai[12] and first success achieved by Strong of Australia[13] in July 1989. Under stringent review and auspices of the internal review board[14], the Chicago group led by Broelsch developed the first adult-to-child LDLT program[15]. Small series of adult-to-child LLDT were then reported from the United States[16] and Europe[17].

The problem of deceased donor liver graft shortage has been particularly severe in Asia[18]. In Japan, where deceased donor graft donation was non-existent[19] and liver surgery already well-developed, LDLT flourished[20,21]. For adult-to-adult LDLT (ALDLT), the left liver was used initially and was reported by the Shinshu group[22]. The left lobe used for adults was very often handicapped by the inadequate graft size. In 1993, Kyoto reported their improvisation of using the right lobe in a case of adult-to-child LDLT for a 9-year old recipient. The intention in this particular case was to avoid precarious arterial anatomy of the donor's left lobe[23]. The first case of right lobe ALDLT was performed at Queen Mary Hospital, the University of Hong Kong on May 10th 1996. A priori, the right liver
Donor right hepatectomy is one of the most major surgical living donor procedures. Subjecting a donor who has no medical indication for surgery to a major surgical operation with attendant risks is an ethical challenge. It was viewed by the medical community and the society with caution and skepticism. Such donor procedure could only be partially justified by the benefit on the recipient and exhaustion of alternatives. This view is not universally accepted. Our common ground is the commitment to provide care of the highest standard to the living liver donor. Efforts for the betterment of care for the donors and yet not depriving them of the chance of saving or improving the life of their beloved recipients should worth dedication and ingenuity of the transplant community.

DONOR SAFETY AND WELLBEING
Donor safety is central to LDLT. As the application of LDLT extended from children to adults, and from using the left liver graft to the right liver graft, the dilemma between recipient success and donor risk came to the spotlight. The reported overall complication rate of donors is around 20%, but as high as 67% in one review. A unified system of complication reporting may narrow this range. Not only does the complication rate vary amongst different centers, the types of complications reported also vary. The most common complications are wound infection, ileus, and bile leakage. With accumulation of experience, donor morbidity could be lower than 20%. The majority of complications are of Grade I and were wound infections. With careful attention to biliary anatomy and guidance from intraoperative cholangiography, biliary complications are avoidable. While one donor mortality is too many for the transplant community, there are already 14 known donor deaths. Donor right hepatectomy carries a 0.5% donor mortality rate. Similarly, the causes of donor mortality also vary. A widely publicized case is a male donor in New York who succumbed to gas gangrene of Clostridium perfringens. A hypertensive lady in Japan died from liver failure after right liver donation with a residual left liver with nonalcoholic steatohepatitis 28% of the total liver volume. Fatal pulmonary embolism also occurred in a left liver donor. A donor mother with a history of substance abuse also died from drug overdose 2 mo after donation to her 3-year-old son. In other words, achieving a five-year recipient survival of 80%, it takes one donor life to save 160 recipients. Less tangible is the quality of life changes of the donor in comparison to the predonation state. The long-term biological consequences of donor hepatectomy are not fully known. Nevertheless, there are demonstrable drops in white cell count, platelet counts and elevation of liver transaminases even two years after right liver donation. Quantification of such is mandatory in defining the field strength of LDLT. Detail of the holistic care of living liver donors deserves elaboration in a separate synopsis.

As agreed by the liver transplant community, living liver donors should be of good health and the donor operation performed by experienced centers. There should be no compromise of accepting potential donors with suboptimal physical and mental health. This is the only way to maintain or decrease donor mortality and morbidity.

RECIPIENT SHORT-TERM OUTCOMES

Graft size
Recipient survival is dependent on adequate graft size in relation to recipient body size. Pathophysiology of the small-for-size graft and small-for-size syndrome is then defined. Features include hepatocyte ballooning, steatosis, centrilobular necrosis, and parenchymal cholestasis. Pre-existing portal hypertension of the recipient increases the size requirement of graft.

Anecdotal success of using a very small graft for ALDLT 25% of the estimated standard liver weight and even 20% with portosystemic shunting has been reported. The paradigm shift from the left liver to the right liver enables adult recipients to undergo LDLT. With technical maturity, 35% of the estimated standard liver weight remains the minimum requirement of a graft for predictable recipient success. Portal hyperperfusion and portal hypertension are now conceived as possible mechanisms conducive to damage of small-for-size grafts. A battery of techniques for alleviation of portal venous flow was described. This includes superior mesenteric vein to mesocaval shunt, hemiportocaval shunting, inflow modulation by splenic artery ligation. With portosystemic shunting using a saphenous vein interpositional graft between the right portal vein and right hepatic vein stump, a left lobe 20% of the estimated standard liver mass had been transplanted successfully in one patient. Pharmacological manipulation is on the horizon as well.

More basic to these is the accurate assessment of standard liver volume of the recipient and thus the minimum graft size requirements. There have been a number of formulae developed from the west and one from Japan. A formula derived from Chinese and for application in Chinese which is also gender dependent has been developed and for validation.

Middle hepatic vein
Center to the controversy of right lobe ALDLT is inclusion of the MHV or otherwise. Deleterious effects of no drainage to the segments 5 and 8 include severe venous congestion and necrosis of these segments. Surgical decision of not including the MHV includes demonstration of collaterals between segment 5 and 8 tributaries and the right hepatic vein. Kyoto University devised an algorithm which includes the MHV when the graft is MHV dominant, or the graft to recipient weight ratio less than 1%, and in all cases, remnant left lobe larger than 35%. Surgical decision of not including the MHV includes demonstration of collaterals between segment 5 and 8 tributaries and the right hepatic vein. Chang Gung Memorial Hospital includes the MHV when the graft is MHV dominant, or the graft to recipient weight ratio less than 1%, and in all cases, remnant left lobe larger than 35%. Tokyo University ingeniously observed congestion of segments 5 and 8 of the graft after temporary clamping of the right hepatic artery before determining venous interpositional grafting.
We include the MHV in all right liver grafts for simplicity and familiarity of the technique. Irrespective of the venous drainage pattern of segment 4 of the remnant left liver, the segment 4b hepatic vein is preserved. utmost care is needed for its preservation when it drains into the MHV. The outflow capacity is guaranteed by venoplasty on the back-table of the MHV and right hepatic vein into a single cuff. The venoplasty is further marked by a more expedient hepatic vein to inferior vena cava anastomosis and higher outflow capacity of the right liver graft.

In summary, adequate graft size and quality, excellent venous outflow, and moderate portal inflow are keys to success of ALDLT.

**High urgency LDLT**

ALDLT under high urgency was impetus to development of liver transplant in our center. Early experience of a number of centers showed inferior surgical outcomes of ALDLT in the high urgency situation. With accumulation of experience and right liver graft incorporating the MHV, surgical outcomes of ALDLT is not compromised. We also showed that ALDLT improves the survival of potential recipients. The question of when a patient becomes too sick for liver transplantation is to be answered. To justify ALDLT, good recipient outcome and acceptable donor morbidity, and voluntarism of the donor are the least that could be expected. The Live Organ Donor Consensus Group has largely supported this viewpoint. The Model for End-Stage Liver Disease score has been validated as a factor predictive of recipient short-term survival in DDLT. Data from ALDLT in North America and Europe, however, do not support this view. Outside Asia, ALDLT is gradually considered a standard treatment for acute liver failure.

**Biliary reconstruction**

Biliary complication justifies itself the Achilles' heel of DDLT and is even more convincing in ALDLT. Hepaticojejunostomy and duct-to-duct anastomosis have no substantial difference in the incidence of biliary complications. Nonetheless, duct-to-duct anastomosis reduces the operating time and avoids contamination of the operation field, expedites return of bowel functions, and avoids internal herniation of bowel loops. It also allows subsequent intervention by endoscopic retrograde cholangiopancreatography. In some centers, duct-to-duct anastomosis is stented to minimize the chance of stenosis and leakage. Whether the stent plays a role in the postoperative period, or in facilitating anastomosis, or both, has not been validated. Furthermore, whether continuous or interrupted sutures makes a difference is unknown. A study on DDLT which showed no difference may not be applicable to ALDLT. Randomized controlled trials of recipients allocated to both arms may answer these questions.

**RECIPIENT LONG-TERM OUTCOMES**

**Hepatocellular carcinoma**

Early efforts of transplanting patients with advanced unresectable primary liver cancers were tempered by invariable relapse of malignancy. Further work of the same group established the correlation between poor prognosis and high pathological tumor-node-metastasis staging. Vascular invasion by tumor is the single most important factor in treatment failure of ALDLT for unresectable small hepatocellular carcinoma (HCC). Major vascular invasions though apparent for large tumors, may not be so for the small ones. Now called the Milan Criteria and the University of San Francisco Criteria (UCSF), the tumor size and number are used as surrogate parameters for likelihood of vascular invasion. The Milan criteria are based on pretreatment imaging, whereas the UCSF criteria on liver explant histopathology. Accuracy of preoperative imaging in staging is inadequate. The tendency is toward underestimation of tumor load. Even in studies with good image to histopathology correlation, underestimation is common. Tumor grade and tumor size are predictors of vascular invasion. Tumor size itself is also a predictor of tumor grade.

In our own series of ALDLT for HCC, there is a tendency of a higher recurrence rate compared with DDLT. It is postulated that the higher regeneration rate and reperfusion injury of small grafts in ALDLT provides an environment favorable for HCC cell implantation and growth in the graft. It is also possible that in ALDLT, for preservation of the inferior vena cava, more liver manipulation is required leading to tumor compression and cancer cell dissemination. However, it is not unlikely that patients who have received DDLT are the self-selected patients because only candidates with slowly growing HCC who could wait for deceased donor liver grafts could receive the transplantation as the cancer cells are less aggressive. In fact, fast-tracking ALDLT for HCC had a higher recurrence rate. Further studies on patient selection criteria and innovation of surgical technique are required to improve the long-term outcome of ALDLT for HCC. A recent series from Korea, nonetheless, has comparable results as DDLT.

In a series of 316 recipients with HCC who underwent ALDLT in Japan, the patient and recurrence-free survival rates were significantly worse if the Milan's criteria were not met. However, within this series, 171 (54.1%) of the recipients did not fulfill the Milan's criteria, and 176 were staged Ia. The alpha-fetoprotein level, tumor size, vascular invasion, and bilobar distribution were independent risk factors for HCC recurrence. The grade of histological differentiation of HCC showed close correlation with tumor characteristics and recurrence. Multifocal HCC verified by histopathology after transplantation with no recurrence was reported. A policy of extended indication beyond the Milan and UCSF criteria is being validated.

The first use of sirolimus in liver transplantation was in patients with liver cancer, using the reported antitumor effects of the drug. Subsequent work has shown efficacy of the drug in the inhibition of hepatocellular tumor cell lines. Recipients transplanted for HCC and received sirolimus and low dose tacrolimus survived longer.

**Sequelae of long-term immunosuppression**

Calcineurin inhibitors greatly improve graft and recipient
survivals. The lowest permissible serum drug level is employed to minimize the side effects. Nonetheless, two undesirable results still occur in recipients, i.e. renal impairment and tendency toward diabetes. A trend toward steroid-sparing immunosuppression seems workable.

The added benefit of the potential antineoplastic property of sirolimus makes it very attractive for recipients with any other organs. Clinical application of cyclosporine frequently in humans after transplantation of the liver than programs. Drug-free tolerance was observed more with cyclosporin A used in solid organ transplantation.

Prompted by development of immune tolerance of noncompliant liver recipient after cessation of immunosuppressant therapy, weaning programs were incorporated into a long-term strategy of liver transplant programs. Drug-free tolerance was observed more frequently in humans after transplantation of the liver than of any other organs. Clinical application of cyclosporiner and then tacrolimus dramatically prevented acute rejection of transplanted organs. However, drug-free tolerance became rare with the dominance of multiagent prophylactic immunosuppression.

Development of tolerance to the graft obviates the use of immunosuppressant with the side effects. The equivalence of solid organ and bone marrow transplantation is substantiated by documentation of systemic microchimerism. Liver cells were identified in distant organs and host cells were also identified in liver grafts. The mirror image of solid organ and bone marrow transplantation envisioned by Starzl brings to light the practicality of long-term donor specific tolerance. The liver as a privileged graft is a constant source of donor leukocyte, thus facilitates the process of clonal exhaustion-deletion especially in the early post-transplant phase under low immunosuppression pretransplant with antilymphocyte globulin. The concept of prope tolerance is also proposed as a means to a similar condition at a lesser degree. Utilizing a powerful lymphocyte-depleting antibody, Campath 1H, half-dose cyclosporine monotherapy became workable. During a window of opportunity for immunologic engagement (WOFIE), it is hypothesized that there is engagement of donor and recipient marrow cells. Not until the availability of transgenic xenografts, effective and specific immunosuppression remains the practical way to graft maintenance. Nonetheless, continual assessment of the risk of chronic subclinical rejection is necessary.

**CONCLUSION**

At a minimum, recipient success is high and donor risk low. This brings donor and recipient issues into a close relationship. Conceptually, it would be inappropriate to accept a higher risk for the donor simply because of the improvement of recipient outcome. It is nonetheless our common goal to improve the standard of recipient and donor operations. What the public should change is, however, the better acceptance of ALDLT in the face of better safety and success, while the effort to make more deceased donor grafts available is never be forgotten.

Now we have near perfect graft harvesting and implantation techniques. Excluding patients with prohibitive conditions, e.g. uncontrolled sepsis and poor cardiac conditions, the short-term success is predictable. We still require selecting patients with a low recurrence rate of HCC and hepatitis C after transplantation. A lower biliary complication rate is welcome and could only be reduced by better preservation of biliary vasculature on the donor and the recipient and careful anastomotic techniques.

Donor safety and recipient success are inseparable. While donor mortality is a reality, it is by lowering donor mortality and improving recipient survival the justification of LDLT becomes stronger.

Although the major interest of the liver transplant community was in ALDLT in the last decade, the success of ALDLT has been a result of the ground works laid since the sixties. Key publications documenting the major achievements in liver transplantation leading to the ever improving results of ALDLT are listed in chronological order in Table 1.

### Table 1 Landmark publications of liver transplantation in chronological order

| Author | Discovery and application | Year of publication |
|--------|---------------------------|---------------------|
| Starzl | First attempts of DDLT in human | 1963 |
| Starzl | First long survival DDLT recipients | 1968 |
| Smith | Conceptualization of LDLT | 1969 |
| Calne | Cyclosporin A used in solid organ transplantation | 1979 |
| Bismuth | First adult-to-child reduced-size DDLT | 1984 |
| Pichlmayr | Split-graft DDLT for 2 recipients | 1988 |
| Belzer | Clinical use of University of Wisconsin Solution | 1990 |
| Raia | First attempt of LDLT (December 1988) | 1989 |
| Strong | First successful LDLT from adult to child (July 1989) | 1990 |
| Yamaoka | First report of right liver graft from adult to child (1992) | 1994 |
| Hashikura | First successful left liver adult-to-adult LDLT (November 1993) | 1994 |
| Lo | First right liver adult-to-adult LDLT using right liver (May 1996) | 1997 |

**REFERENCES**

1. Raia S, Nery JR, Mies S. Liver transplantation from live donors. *Lancet* 1989; 2: 497
2. Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, Abu-Elmagd K, Marsh W, Madariaga J, Mazariegos G, Geller D, Bonham CA, Gayowski T, Cacciarelli T, Fontes P, Starzl TE, Fung JJ. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. *Ann Surg* 2000; 232: 490-500
3. Busuttil RW, Farmer DC, Yerisiz H, Hiatt JR, McDiarmid SV, Goldstein LJ, Saab S, Han S, Durazo F, Weaver M, Cao C, Chen T, Lipshtuz GS, Holt C, Gordon S, Gornbein J, Amersi F, Ghobrial RM. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. *Ann Surg* 2005; 241: 905-916; discussion 916-918
4. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, rittain RS, addel WR. Homotransplantation of the liver in humans. *Surg Gynecol Obstet* 1963; 117: 659-676
5. Starzl TE, Groth CG, Brettschneider L, Penn I, Fulginiti VA, Moon JB, Blanchard H, Martin AJ Jr, Porter KA. Orthotopic homotransplantation of the human liver. *Ann Surg* 1968; 168: 392-415
Chan SC et al. Historical perspective of LDLT

6 Calne  RY, Rolles K, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Henderson RG, Azziz S, Lewis P. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 1033-1036.

7 Belzer FO, Kalayoglu M, D’Alessandro AM, Pirsch JD. Sollinger HW, Hoffmann R, Boudjema K, Southard JH. Organ preservation: experience with University of Wisconsin solution and plans for the future. Clin Transplant 1990; 4: 73-77.

8 Bismuth H, Houssin D. Reduced-sized orthotopic liver graft in hepatic transplantation in children. Surgery 1984; 95: 367-370.

9 Pichlmayr R, Ringe B, Gubernatis G, Hauss J, Benzendahl EF. Transplantation of a donor liver to 2 recipients (splitting transplantation)—a new method in the further development of segmental liver transplantation. Langenbecks Arch Chir 1988; 373: 127-130.

10 Broelsch CE, Emond JC, Whittington PF, Thistlethwaite Jr, Baker AL, Lichtor JL. Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants. Ann Surg 1990; 212: 368-375; discussion 375-377.

11 Smith B. Segmental liver transplantation from a living donor. J Pediatr Surg 1969; 4: 126-132.

12 Strong RW, Lynch SV, Ong TH, Matsunami H, Koido Y, Balderson GA. Successful liver transplantation from a living donor to her son. N Engl J Med 1990; 322: 1505-1507.

13 Singer PA, Siegler M, Whittington PF, Lantos JD, Emond JC, Thistlethwaite JR, Broelsch CE. Ethics of liver transplantation with living donors. N Engl J Med 1988; 321: 623-622.

14 Broelsch CE, Whittington PF, Emond JC, Heffron TG, Thistlethwaite JR, Stevens L, Piper J, Whittington SH, Lichtor JL. Liver transplantation in children from living related donors. Surgical techniques and results. Ann Surg 1991; 214: 428-437; discussion 437-439.

15 Malago M, Rogiers X, Burdelski M, Broelsch CE. Living related liver transplantation: 36 cases at the University of Hamburg. Transplant Proc 1994; 26: 3620-3621.

16 Chen CL, Fan ST, Lee SG, Mukuchi M, Tanaka K. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003; 75: S6-S11.

17 Nudeshima J. Obstacles to brain death and organ transplantation in Japan. Lancet 1991; 338: 1063-1064.

18 Mukauchi M, Kawarazaki H, Iwanaka T, Kamada N, Takayama T, Kumon M. Living related liver transplantation. Surg Today 1992; 22: 297-301.

19 Ozawa K, Uemoto S, Tanaka K, Kumada K, Yamaoka Y, Kobayashi N, Inamoto T, Shimahara Y, Mori K, Honda K. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. Ann Surg 1992; 216: 547-553.

20 Hashikura Y, Mukuchi M, Kawasaki S, Matsunami H, Ikegami T, Nakazawa Y, Kiyosawa K, Ichida T. Successful living-related partial liver transplantation to an adult patient. Lancet 1994; 343: 1233-1234.

21 Yamaoka Y, Washida M, Honda K, Tanaka K, Mori K, Shimahara Y, Okamoto S, Ueda M, Hayashi M, Tanaka A. Liver transplantation using a right lobe graft from a living related donor. Transplantation 1994; 57: 1127-1130.

22 Lo CM, Fan ST, Liu CL, Lo RJ, Lau GK, Wei WI, Li JH, Ng IO. Wong J. Extending the limit on the size of adult recipient in living donor liver transplantation using extended right lobe grafts. Transplantation 1999; 67: 1524-1528.

23 Lo CM, Fan ST, Liu CL, Wei WI, Lo RJ, Lai CL, Chan JK, Ng IO, Fung A, Wong J. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Transplantation 1997; 226: 261-269; discussion 269-270.

24 Strong RW. Whither living donor liver transplantation? Liver Transpl Surg 1999; 5: 536-538.

25 Surman OS. The ethics of partial-liver donation. N Engl J Med 2002; 346: 1038.

26 Cronin DC 2nd, Millis JM, Siegler M. Transplantation of liver grafts from living donors into adults—too much, too soon. N Engl J Med 2001; 344: 1633-1637.

27 Beavers KL, Sandler RS, Shrestha R. Donor morbidity associated with right lobectomy for living donor liver transplantation to adult recipients: a systematic review. Liver Transpl 2002; 8: 110-117.

28 Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.

29 Chan SC, Fan ST, Lo CM, Liu CL, Wong J. Toward current standards of donor right hepatectomy for adult-to-adult live donor liver transplantation through the experience of 200 cases. Am J Surg 2007; 294: 110-117.

30 Barr ML, Belghiti J, Villamil FG, Pomfret EA, Sutherland DS, Gruesner RW, Langnas AN, Delmonico FL. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation 2006; 81: 1373-1385.

31 Trotter JF, Adam R, Lo CM, Kenison J. Documented deaths of hepatic lobe donors for living donor liver transplantation. Liver Transpl 2006; 12: 1485-1488.

32 Miller C, Florman S, Kim-Schluger L, Lento P, De La Garza J, Wu J, Xie B, Zhang W, Bottone E, Zhang D, Schwartz M. Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl 2004; 10: 1315-1319.

33 Akabayashi A, Slingsby BT, Fujita M. The first donor death after living-related liver transplantation in Japan. Transplantation 2004; 77: 634.

34 Malago M, Rogiers X, Burdelski M, Broelsch CE. Living related liver transplantation: 36 cases at the University of Hamburg. Transplant Proc 1994; 26: 3620-3621.

35 Ringe B, Petrucci RJ, Soriano HE, Reynolds JC, Meyers WC. Death of a living liver donor from illicit drugs. Liver Transpl 2007; 13: 1193-1194.

36 Chan SC, Lo CM, Wong Y, Liu CL, Fan ST. Long-term biological consequences of donor right hepatectomy including the middle hepatic vein in adult-to-adult live donor liver transplantation. Liver Transpl 2006; 12: 259-263.

37 Malago M, Testa G, Marcos A, Fung JJ, Siegler M, Cronin DC, Broelsch CE. Ethical considerations and rationale of adult-to-adult living donor liver transplantation. Liver Transpl 2001; 7: 921-927.

38 Kiuchi T, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, Egawa H, Fujita S, Hayashi M, Tanaka K. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999; 67: 321-327.

39 Emond JC, Renz JF, Ferrell LD, Rosenthal P, Lim RC, Roberts JP, Lake JR, Ascher NL. Functional analysis of grafts from living donors. Implications for the treatment of older recipients. Ann Surg 1996; 224: 552-552; discussion 552-554.

40 Ben-Haim M, Emsre S, Fishbein TM, Sheiner PA, Bodian CA, Kim-Schluger L, Schwartz ME, Miller CM. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl 2001; 7: 948-953.

41 Lo CM, Fan ST, Chan JK, Wei W, Lo RJ, Lai CL. Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation 1996; 62: 696-698.

42 Masetti M, Siniscalchi A, De Pietri L, Braglia V, Benedetto F, Di Cautero N, Begliomini B, Romano A, Miller CM, Ramacciato G, Pinna AD. Living donor liver transplantation with left liver graft. Am J Transplant 2004; 4: 1713-1716.

43 Tanaka K, Yamada T. Living donor liver transplantation in Japan and Kyoto University: what can we learn? J Hepatol 2005; 42: 25-28.

44 Fan ST, Lo CM, Liu CL, Yong BH, Wong J. Determinants of hospital mortality of adult recipients of right lobe live donor liver transplantation. Ann Surg 2003; 238: 864-869; discussion 869-870.

45 Man K, Lo CM, Ng IO, Wong YC, Qin LF, Fan ST, Wong J. Liver transplantation in rats using small-for-size grafts: a study of hemodynamic and morphological changes. Arch Surg 2001; 136: 280-285.

www.wjgnet.com
54 Man K, Fan ST, Lo CM, Liu CL, Fung PC, Liang TB, Lee TK, Tsui SH, Ng IO, Zhang ZW, Wong J. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg 2003; 237: 256-264

55 Boilott O, Delafosse B, Mechet I, Boucaud C, Pouyet M. Small-for-size partial liver graft in an adult recipient; a new transplant technique. Lancet 2002; 359: 406-407

56 Troisi R, Ricciardi S, Smeets P, Petrovic M, Van Maele G, Collé I, Van Vlerbergh H, de Hemptinne B. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Ann Surg Transplant 2005; 5: 1397-1404

57 Lo CM, Liu CL, Fan ST. Portal hyperperfusion injury as the cause of primary nonfunction in a small-for-size graft: successful treatment with splenic artery ligation. Liver Transpl 2003; 9: 626-628

58 Man K, Lee TK, Liang TB, Lo CM, Fung PC, Tsui SH, Li XL, Ng KT, Fan ST. FK 409 ameliorates small-for-size graft liver injury by attenuation of portal hypertension and downregulation of Egr-1 pathway. Ann Surg 2004; 230: 159-168

59 Vauthy JN, Abdalla EK, Doherty DA, Gertsch P, Fensternacher MJ, Loyer EM, Lerut J, Materne R, Wang X, Fenstermacher MJ, Loyer EM, Lerut J, Materne R, Wang X, Chouker A, Martignoni A, Dugas M, Eisenmenger W, Schauer RW. MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 2003; 9: 473-476

60 Abcassissi M, Adams M, Adams P, Arnold RM, Atkins CR, Barr ML, Bennett WM, Bia M, Briscoe DM, Burdick J, Corry RJ, Davis J, Delmonico FL, Gaston RS, Harmon W, Jacobs CL, Kahn J, Leichtman A, Miller C, Moss D, Newmann JM, Rosen LS, Simonelli L, Spital A, Starnes VA, Thomas C, Tyler LS, Williams L, Wright FH, Youngner S. Consensus statement on the living organ donor. JAMA 2000; 284: 2919-2926

61 Saab S, Wang V, Ibrahim AB, Durazo F, Han S, Farmer DG, Yersiz H, Morrisey M, Goldstein LB, Ghobrial RM, Busuttil RW. MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 2003; 9: 473-476

62 Castaldo ET, Pinson CW, Feurer ID, Wright JK, Gorden DL, Kelly BS, Chari RS. Continuous versus interrupted suture for end-to-end biliary anastomosis during liver transplantation gives equal results. Liver Transpl 2007; 13: 234-238

63 Itanos S, Yoshikawa K, Yamaoka Y, Regimbeau JM, Belghiti J, Curley SA. Liver transplantation in cancer therapy. Ann Surg 1996; 2262-2264

64 Schwartz M. Liver transplantation for hepatocellular carcinoma. Semin Surg Oncol 1993; 9: 337-340

65 Mazzaferrero V, Regalia E, Doni R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammata M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699

66 Makuuchi M. Right liver graft without middle hepatic vein reconstruction from the living donor. Surgery 2005; 137: 1317-1321

67 Cescon M, Sugawara Y, Sano K, Ohkubo T, Kaneko J, Makuuchi M. Right liver graft without middle hepatic vein reconstruction from a living donor. Transplantation 2002; 73: 1164-1166

68 de Vila VH, Chen CL, Chen YS, Wang CC, Lin CC, Cheng YF, Huang TL, Jawan B, Eng HL. Right lobe living donor liver transplantation-addressing the middle hepatic vein controversy. Ann Surg 2003; 238: 275-282

69 Man K, Makuuchi M, Miki K, Maema A, Sugawara Y, Imamura H, Matsunami H, Takeuchi H, Takenaka K, Morita K, Nishizawa T, Watanabe M, Makuuchi M, Maema A, Sugawara Y, Sano K. Age and gender. Liver Transpl 2004; 10: 678-685

70 Chan SC, Makuuchi M, Miki K, Maema A, Sugawara Y, Sano K, Ohkubo T, Kaneko J, Makuuchi M, Maema A, Sugawara Y, Min P. Congestion of right liver graft in living donor liver transplantation. Transplantation 2001; 71: 812-814

71 Cescon M, Sugawara Y, Sano K, Ohkubo T, Kaneko J, Makuuchi M. Right liver graft without middle hepatic vein reconstruction from a living donor. Transplantation 2002; 73: 1164-1166

72 de Vila VH, Chen CL, Chen YS, Wang CC, Lin CC, Cheng YF, Huang TL, Jawan B, Eng HL. Right lobe living donor liver transplantation-addressing the middle hepatic vein controversy. Ann Surg 2003; 238: 275-282

73 Cescon M, Sugawara Y, Sano K, Ohkubo T, Kaneko J, Makuuchi M. Right liver graft without middle hepatic vein reconstruction from a living donor. Transplantation 2002; 73: 1164-1166

74 Fan ST, Lo CM, Liu CL, Wang WX, Wong J. Safety and necessity of including the middle hepatic vein in the right lobe graft in adult-to-adult live donor liver transplantation. Ann Surg 2003; 238: 137-148

75 Fan ST, Lo CM, Liu CL, Wang WX, Wong J. Tailoring donor hepatopexy per segment 4 venous drainage in right lobe live donor liver transplantation. Liver Transpl 2004; 10: 755-762

76 Lo CM, Fan ST, Liu CL, Wong J. Hepatic venoplasty in living-donor liver transplantation using right lobe graft with middle hepatic vein. Transplantation 2003; 75: 358-360

77 Liu CL, Zhao Y, Fan ST. Hepatic venoplasty in right lobe live donor liver transplantation. Liver Transplant 2003; 9: 1265-1272

78 Fan ST. Live donor liver transplantation in adults. Transplantation 2006; 82: 723-732
carcinoma. *Gastroenterology* 2004; 127: S268-S276

82 Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. *Liver Transpl* 2005; 11: 1086-1092

83 Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. *Br J Surg* 2007; 94: 78-86

84 Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. *Gastroenterology* 2004; 127: S277-S282

85 Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. *Liver Transpl* 2005; 11: 1265-1272

86 Hirohashi K, Yamamoto T, Shuto T, Uenishi T, Ogawa M, Sakabe K, Tanaka S, Kanazawa A, Tanaka H, Kubo S, Kinoshita H. Multifocal hepatocellular carcinoma in patients undergoing living-related liver transplantation. *Hepatogastroenterology* 2003; 50: 1617-1620

87 Kaihara S, Kiuchi T, Ueda M, Oike F, Fujimoto Y, Ogawa K, Kozaki K, Tanaka K. Living-donor liver transplantation for hepatocellular carcinoma. *Transplantation* 2003; 75: S37-S40

88 Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. *J Antibiot (Tokyo)* 1984; 37: 1231-1237

89 Schumacher G, Oidtmann M, Ruegggeber A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, Bahra M, Neuhaus P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. *World J Gastroenterol* 2005; 11: 1420-1425

90 Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. *Clin Cancer Res* 2004; 10: 8421-8425

91 Kneteman NM, Oberholzer J, Al Saghir M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. *Liver Transpl* 2004; 10: 1301-1311

92 Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. *Liver Transpl* 2004; 10: 728-733

93 Fung J, Marcos A. Rapamycin: friend, foe, or misunderstood? *Liver Transpl* 2003; 9: 469-472

94 Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. *Lancet* 1989; 2: 1000-1004

95 Starzl TE, Murase N, Demetris AJ, Trucco M, Abu-Elmagd K, Gray EA, Eghtesad B, Shapiro R, Marcos A, Fung JJ. Lessons of organ-induced tolerance learned from historical clinical experience. *Transplantation* 2004; 77: 926-929

96 Starzl TE. The mystique of organ transplantation. *J Am Coll Surg* 2005; 201: 160-170

97 Starzl TE. The “privileged” liver and hepatic tolerogenicity. *Liver Transpl* 2001; 7: 918-920

98 Calne R. “Prope” tolerance: induction, lymphocyte depletion with minimal maintenance. *Transplantation* 2005; 80: 6-7

99 Mazariogios GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W, McMichael J, Fung JJ, Starzl TE. Weaning of immunosuppression in liver transplant recipients. *Transplantation* 1997; 63: 243-249

S- Editor Liu Y  L- Editor Rippe RA  E- Editor Li HY

www.wjgnet.com